Back to search results

Prostate Cancer Study: Abiraterone, Prednisone, and ADT with Radiation

This study is for men with prostate cancer that has spread to their pelvic lymph nodes, but these nodes are still small (less than 1 cm). Doctors are using a new imaging test called PSMA-PET to find these small areas. The study compares two treatments: standard hormone therapy (Androgen Deprivation Therapy or ADT) with radiation therapy, versus an enhanced ADT that includes abiraterone and prednisone, also with radiation therapy. The main goal is to see how many men are free from their cancer for five years after treatment. You may be able to join if you have a confirmed prostate cancer diagnosis, PSMA-positive pelvic lymph nodes under 1 cm, and haven't had prior treatment for your prostate cancer.

Study design
This study will involve 140 participants who will be randomly assigned to one of two treatment groups. It compares two different treatment approaches for prostate cancer.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to measure their failure-free survival rate for up to 5 years after randomization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07237269

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

Recruiting
PHASE2Ages 30+InterventionalTreatment
University of Nebraska
~140 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Androgen Deprivation Therapy (ADT)AbirateronePrednisoneRadiation Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
5-year failure-free survival rate
Measured over From randomization up to 5 years

Conditions

Prostate Cancer

Explore related trials

Prostate CarcinomaFOLH1 Gene

Where it's being run

1 sites across 1 states
Nebraska1

Study leadership

  • Michael Baine, MD, PhD · PRINCIPAL_INVESTIGATOR · Fred & Pamela Buffett Cancer Center, University of Nebraska, 987521 Nebraska Medical Center

Who to contact

Taylor Johnson, MA
[email protected]
402-559-4596
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • 5-year failure-free survival rateFrom randomization up to 5 years

    Determine the impact of enhanced ADT with abiraterone/prednisone versus standard ADT on the 5-year failure-free survival of patients with PSMA-positive conventionally negative pelvic lymphadenopathy (i.e. \<1cm in smallest diameter).